The Many Faces of Tau
Mass spectrometry reveals distinct tau chemistries across Alzheimer’s and related dementias
Clinical Scorecard: The Many Faces of Tau
At a Glance
| Category | Detail |
|---|
| Condition | Tauopathies |
| Key Mechanisms | Pathological tau protein aggregation with distinct chemical signatures across neurodegenerative diseases. |
| Target Population | Individuals with tau-related dementias, including Alzheimer's disease, CTE, progressive supranuclear palsy, and Pick's disease. |
| Care Setting | Clinical research and diagnostic laboratories. |
Key Highlights
- Distinct tau chemical signatures characterize over 20 neurodegenerative diseases.
- FLEXITau workflow enables precise measurement of pathological tau and its modifications.
- Machine learning identifies key tau modifications for diagnostics and drug development.
- Each tauopathy has a unique combination of post-translational modifications and cleavage patterns.
- Absolute quantification of tau modifications is essential for effective diagnostics and treatment.
Guideline-Based Recommendations
Diagnosis
- Utilize disease-specific tau modifications for accurate diagnostics.
Management
- Target identified post-translational modifications in therapeutic development.
Monitoring & Follow-up
- Quantify pathological tau levels to assess disease progression.
Risks
- Low abundance modifications may not be viable targets for treatment.
Patient & Prescribing Data
Patients diagnosed with tauopathies.
Focus on the most relevant tau modifications for tailored therapeutic approaches.
Clinical Best Practices
- Incorporate quantitative proteomics in diagnostic workflows.
- Apply machine learning to prioritize tau modifications for research and treatment.
- Ensure absolute quantification of molecular targets for effective drug design.
References
